HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: dc06-2272v1 30/7/1689    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahler, K. H. Articles by Pogach, L. M. Search for Related Content PubMed PubMed Citation Articles by Kahler, K. H. Articles by Pogach, L. M. Social Bookmarking                What's this?

Impact of Oral Antihyperglycemic Therapy on All-Cause Mortality Among Patients With Diabetes in the Veterans Health Administration

¹ Center for Health Care Knowledge and Management, VA New Jersey Health Care System, East Orange, New Jersey
² School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey
³ Deep South Center on Effectiveness, Birmingham VA Medical Center, Birmingham, Alabama

Address correspondence and reprint requests to Kristijan H. Kahler, PhD, RPh, Novartis Pharmaceuticals, One Health Plaza, Room 405/3117, East Hanover, NJ 07936. E-mail: kristijan.kahler{at}novartis.com

OBJECTIVE— The objective of this analysis was to evaluate the impact of several classes of oral antihyperglycemic therapy relative to sulfonylurea monotherapy on all-cause mortality among a cohort of patients with diabetes from the Veterans Health Administration (VHA).

RESEARCH DESIGN AND METHODS— A retrospective cohort study using data obtained from the VHA Diabetes Epidemiology Cohort was used. Users of oral antihyperglycemic therapy were classified into the following cohorts: sulfonylurea monotherapy, metformin monotherapy, metformin plus sulfonylurea, thiazolidinedione (TZD) use alone or in combination with other oral agents (TZD users), and no drug therapy. All-cause mortality was the outcome of interest. Multivariate mixed models incorporating a propensity score to account for imbalance among cohorts were used to estimate drug effects on mortality with associated 95% CIs.

RESULTS— A total of 39,721 patients with diabetes were included in the study. Adjusted odds ratios and 95% CIs for all-cause mortality were 0.87 (0.68–1.10) for metformin monotherapy users, 0.92 (0.82–1.05) for metformin plus sulfonylurea users, and 1.04 (0.75–1.46) for TZD users, relative to sulfonylurea monotherapy users.

CONCLUSIONS— We did not find any significant drug effect on all-cause mortality for any oral treatment cohorts relative to sulfonylurea oral monotherapy.

Abbreviations: DEpiC, Diabetes Epidemiology Cohort • LHSVE, Large Health Survey of Veteran Enrollees • TZD, thiazolidinedione • UKPDS, U.K. Prospective Diabetes Study • VHA, Veterans Health Administration

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. H. Halanych, M. M. Safford, W. C. Keys, S. D. Person, J. M. Shikany, Y.-I. Kim, R. M. Centor, and J. J. Allison Burden of Comorbid Medical Conditions and Quality of Diabetes Care Diabetes Care, December 1, 2007; 30(12): 2999 - 3004. [Abstract] [Full Text] [PDF]